The anti-tumor immune response induced by a combination of MAGE-3/MAGE-n-derived peptides

Zhang, Xiumin; Zhang, Yun‐Fei; Huang, Yang; Qu, Ping; Ma, Bin; Si, Shihui; Li, Zengshan; Li, Wenxin; Li, Xia; Ge, Wei; Hu, Peizhen; Sui, Yan-Fang

doi:10.3892/or.20.1.245

Cited by 5 publications

(5 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For example, Gao et al demonstrated that the ratio of activated cytotoxic CD8‐ T cells to inhibitory Tregs in tumor‐infiltrating lymphocytes (TILs) is an independent favorable prognostic factor for disease‐free and overall survival (OS) after surgical resection of HCC . Several human HCC‐specific antigens, including alpha‐fetoprotein (AFP), glypican 3, New York esophageal squamous cell carcinoma 1 (NY‐ESO‐1), melanoma antigen gene A (MAGE‐A), Wilms tumor 1, and human telomerase reverse transcriptase, also have been identified at low levels in patients with HCC. These antigens lead to functional cytotoxic T‐cell response against HCC .…”

Section: Introductionmentioning

confidence: 99%

Immunotherapy in hepatocellular carcinoma: Primed to make a difference?

Harding

Dika

Abou‐Alfa

2015

Cancer

115

View full text Add to dashboard Cite

Page 1 of 27 CancerThis is the author manuscript accepted for publication and has undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the Version record. Please cite this article as doi:10.1002/cncr.29769.This article is protected by copyright. All rights reserved. Accepted ArticleABSTRACT Advanced hepatocellular carcinoma (HCC) carries a dismal prognosis and the current treatment is limited to sorafenib, an agent with modest benefit. Preclinical data indicate that several immunologic mechanisms are at play to promote HCC development and growth while impairing effective antitumor immune surveillance. Several novel approaches geared at manipulating the immune response to HCC have suggested a therapeutic benefit in early stage clinical trials, indicating a real potential to augment tumor-specific immunity and improve outcomes in this disease. Herein, we review the barriers to an effective immune response against HCC and contemporary clinical investigations that may be "primed"to alter the natural history of HCC.

show abstract

Section: Introductionmentioning

confidence: 99%

Immunotherapy in hepatocellular carcinoma: Primed to make a difference?

Harding

Dika

Abou‐Alfa

2015

Cancer

115

View full text Add to dashboard Cite

show abstract

“…Identification of these CTL epitopes allows for clinical applications of these peptides as cancer vaccines for patients with MAGE-n + /HLA-A2 + tumors. Our previous study showed that the combination of MAGE-3 and MAGE-n epitopes induced more effective antitumor immune responses than either of the peptides alone (16). In addition, the peptide-specific activity was observed to be in a MHC-restricted manner.…”

Section: Discussionmentioning

confidence: 99%

Prediction and analysis of HLA-A2/A24-restricted cytotoxic T-lymphocyte epitopes of the tumor antigen MAGE-n using the artificial neural networks method on NetCTL1.2 Server

Zhang

Hong-yuan

et al. 2010

Oncology Letters

Self Cite

View full text Add to dashboard Cite

Abstract.Cancer immunotherapy has become one of the most important therapeutic approaches to cancer in the past two decades. Tumor antigen-derived peptides have been widely used to elicit tumor-specific cytotoxic T lymphocytes (CTLs). Antigen-specific CTLs induced by MAGE-derived peptides have proven to be highly efficacious in the prevention and treatment of various types of tumor. MAGE-n is a new member of the MAGE gene family and has been shown to be closely associated with hepatocellular carcinoma. It is highly homologous to the MAGE-A gene subfamily, particularly to MAGE-3 (93%). MAGE-n-derived peptide QLVFGIEVV is a novel HLA-A2.1-restricted CTL epitope that induces MAGEn-specific CTLs in vitro. Identification of these CTL epitopes may lead to clinical applications of these peptides as cancer vaccines for patients with MAGE-n + /HLA-A2 + tumors. In the present study, HLA-A/A24-restricted CTL epitopes of antigen MAGE-n were predicted using the NetCTL1.2 Server on the web, COMB >0.85. The results showed that the NetCTL1.2 Server prediction method improved prediction efficacy and accuracy. Additionally, 8 HLA-A2-and 9 HLA-A24-restricted CTL epitope candidates (nonamers) derived from the tumor antigen MAGE-n were predicted. These nonamers, following identification via experimentation, may contribute to the development of potential antigen peptide tumor vaccines. IntroductionRecent studies have shown that tumor antigens, particularly tumor-specific antigens, which induce tumor-specific cytotoxic T lymphocytes (CTLs) and damage tumor cells, are a significant component of tumor vaccines. Epitope peptide vaccine has been of particular interest as it induces specific CTL in vitro and in vivo in order to kill target cells. Previously, a number of human genes that code for tumor antigens identified by autologous CTLs were isolated (1,2), and the epitopes derived from these tumor antigens were further identified to serve as targets for CTLs in the context of HLA class I molecules (3). MAGE-n is a newly identified member of the MAGE gene family which was first reported by our laboratory (Genebank, locus no. AF443295) (4), and was also found to be highly homologous to MAGE-A subfamily genes. Since HLA-A2/ A24 is one of the most frequently expressed molecules in the Chinese population (5,6), it is crucial to identify the tumor antigen epitopes which are presented by HLA-A2/A24 and to induce epitope-specific CTLs against tumor cells. The present study reported a simple and efficient bioinformatics method to identify candidate HLA-A2/A24-restricted CTL epitopes from the tumor antigen MAGE-n. Materials and methodsMAGE-n (316 aa) was selected as the antigen of interest in this study. The amino acid sequences of the tumor antigen were obtained from the Genbank database:Methods. HLA-A/A24-restricted CTL epitopes of antigen MAGE-n were predicted using the NetCTL1.2 Server on the web. The NetCTL1.2 Server (http://www.cbs.dtu.dk/services/ NetCTL) was used for CTL epitope prediction according to the following steps: i) input (past...

show abstract

“…MAGE gene-derived peptides are widely expressed in many tumor and are able to stimulate antigen-specific CTL responses against MAGE-expressing cancer cells, resulting in tumor cell lysis. Therefore, thanks to their effectiveness in preventing and treating diverse cancers, MAGE has been used as a target for cancer immunotherapies [ 97 ]. In this Phase I trial, Morse et al [ 96 ] isolated Dex by ultracentrifugation from peripheral blood mononuclear cells and loaded them with MAGE-A3, -A4, -A10, and MAGE-3DPO4 peptides.…”

Section: Evs In Anti-tumor Immunotherapymentioning

confidence: 99%

Extracellular Vesicles and Their Current Role in Cancer Immunotherapy

Giacobino

Canta

Fornaguera

et al. 2021

Cancers

View full text Add to dashboard Cite

Extracellular vesicles (EVs) are natural particles formed by the lipid bilayer and released from almost all cell types to the extracellular environment both under physiological conditions and in presence of a disease. EVs are involved in many biological processes including intercellular communication, acting as natural carriers in the transfer of various biomolecules such as DNA, various RNA types, proteins and different phospholipids. Thanks to their transfer and targeting abilities, they can be employed in drug and gene delivery and have been proposed for the treatment of different diseases, including cancer. Recently, the use of EVs as biological carriers has also been extended to cancer immunotherapy. This new technique of cancer treatment involves the use of EVs to transport molecules capable of triggering an immune response to damage cancer cells. Several studies have analyzed the possibility of using EVs in new cancer vaccines, which represent a particular form of immunotherapy. In the literature there are only few publications that systematically group and collectively discuss these studies. Therefore, the purpose of this review is to illustrate and give a partial reorganization to what has been produced in the literature so far. We provide basic notions on cancer immunotherapy and describe some clinical trials in which therapeutic cancer vaccines are tested. We thus focus attention on the potential of EV-based therapeutic vaccines in the treatment of cancer patients, overviewing the clinically relevant trials, completed or still in progress, which open up new perspectives in the fight against cancer.

show abstract

The anti-tumor immune response induced by a combination of MAGE-3/MAGE-n-derived peptides

Abstract: Abstract. Tumor antigen-derived peptides have been widely used to elicit tumor-specific cytotoxic T lymphocytes (CTLs).

Cited by 5 publications

References 19 publications

Immunotherapy in hepatocellular carcinoma: Primed to make a difference?

Immunotherapy in hepatocellular carcinoma: Primed to make a difference?

Prediction and analysis of HLA-A2/A24-restricted cytotoxic T-lymphocyte epitopes of the tumor antigen MAGE-n using the artificial neural networks method on NetCTL1.2 Server

Extracellular Vesicles and Their Current Role in Cancer Immunotherapy

Contact Info

Product

Resources

About